SEC Contract Filing

Filing Date: 2023-05-30

Document Content:
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>omnibusplan2016wamend5.htm
<DESCRIPTION>EX-10.1
<TEXT>
<HTML>
<HEAD><!-- Document generated by Workiva Inc -->
<TITLE>omnibusplan2016wamend5</TITLE>
</HEAD>
<BODY bgcolor="white">
<DIV align="center">
<DIV style="margin-left:1em;width:1055;"><!-- omnibusplan2016wamend5001.jpg -->
<DIV style="padding-top:2em;">
<IMG src="omnibusplan2016wamend5001.jpg" title="slide1" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white"> EXHIBIT 10.1 ARBUTUS BIOPHARMA CORPORATION 2016 OMNIBUS SHARE AND INCENTIVE PLAN (as adopted by the board of directors on April 6, 2016 and approved by the shareholders on May 19, 2016; and as supplemented by the Committee on May 9, 2019) Section 1. Purpose The purpose of the Plan is to promote the interests of the Company by aiding the Company in attracting and retaining employees, officers, consultants, advisors and non-employee Directors to promote the business and financial success of the Company, to offer such persons incentives to put forth maximum efforts for the success of the Company&#8217;s business and to compensate such persons through various share and cash based arrangements and provide them with opportunities for share ownership in the Company, thereby aligning the interests of such persons with the Company&#8217;s shareholders. Section 2. Definitions As used in the Plan, the following terms shall have the meanings set forth below: (a) &#8220;Affiliate&#8221; shall mean any entity that, directly or indirectly through one or more intermediaries, is controlled by the Company. (b) &#8220;Award&#8221; shall mean any Option, Stock Appreciation Right, Restricted Stock, Restricted Stock Unit, Performance Award, Dividend Equivalent or Other Stock-Based Award granted under the Plan. (c) &#8220;Award Agreement&#8221; shall mean any written agreement, contract or other instrument or document evidencing an Award granted under the Plan (including a document in an electronic medium) executed in accordance with the requirements of Section 9(c). (d) &#8220;Board&#8221; shall mean the Board of Directors of the Company. (e) &#8220;Cause&#8221; in respect of a Participant means: (i) if &#8220;Cause&#8221; is defined in an employment agreement between such Participant and the Company, the meaning of &#8220;Cause&#8221; as provided for in such employment agreement; and (ii) if Cause is not so defined, a circumstance that would entitle the Company to terminate the employment or services of such Participant at law without notice or compensation as a result of such termination; (f) &#8220;Change in Control&#8221; means, unless specified otherwise in an existing agreement with a Participant: (i) the sale of all or substantially all of the assets of the Company to a non-Affiliate; (ii) a merger, reorganization, or consolidation involving the Company in which the voting securities outstanding immediately prior to the transaction represent or are converted into or exchanged for securities of the surviving or resulting entity that, immediately upon completion of the transaction, represent less than 50% of the outstanding voting power of the surviving or resulting entity; (iii) the acquisition of all or a majority of the outstanding voting securities of the Company in a single transaction or a series of related transactions by a person or group of persons; </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- omnibusplan2016wamend5002.jpg -->
<DIV style="padding-top:2em;">
<IMG src="omnibusplan2016wamend5002.jpg" title="slide2" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white"> provided however, that a Change in Control shall not be deemed to have occurred if such Change in Control results solely from the issuance, in connection with a bona fide financing or series of financings by the Company or an Affiliate of the Company, of voting securities of the Company or an Affiliate of the Company or any rights to acquire voting securities of the Company or an Affiliate of the Company which are convertible into voting securities, or if the Company effects a transaction solely to change the Company&#8217;s domicile. (g) &#8220;Committee&#8221; shall mean the Compensation Committee of the Board or such other committee designated by the Board to administer the Plan. The Committee shall be comprised of not less than such number of Directors as shall be required to permit Awards granted under the Plan to qualify under Rule 16b-3, and each member of the Committee shall be a &#8220;non-employee director&#8221; within the meaning of Rule 16b-3 and an &#8220;outside director&#8221; within the meaning of Section 162(m). (h) &#8220;Company&#8221; shall mean Arbutus Biopharma Corporation and any successor corporation. (i) &#8220;Director&#8221; shall mean a member of the Board. (j) &#8220;Dividend Equivalent&#8221; shall mean any right granted under Section 6(e) of the Plan. (k) &#8220;Effective Date&#8221; shall have the meaning ascribed thereto in Section 11 of the Plan; (l) &#8220;Eligible Person&#8221; shall mean any employee, officer, non-employee Director, consultant, independent contractor or advisor providing services to the Company or any Affiliate, or any such person to whom an offer of employment or engagement with the Company or any Affiliate is extended. (m) &#8220;Fair Market Value&#8221; with respect to a Share as of any date shall mean (a) if the Share is listed on any established stock exchange, the price of one Share at the close of the regular trading session of such market or exchange on such date, as reported by The Wall Street Journal or a comparable reporting service, or, if no sale of Shares shall have occurred on such date, on the next preceding date on which there was a sale of Shares; (b) if the Shares are not so listed on any established stock exchange, the average of the closing &#8220;bid&#8221; and &#8220;asked&#8221; prices quo